AZTA

Azenta, Inc.

Azenta, Inc. (AZTA) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (A); its weakest is Value (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
C-
Factor Score 2.0 / 5.0
Growth
C
Factor Score 2.4 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
A
Factor Score 4.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 53.1
EV / EBITDA 46.9
Rev Growth YoY 5.1%
Gross Margin 44.2%
Price Return 3M 43.2%
Price Return 12M 58.0%
Catalyst Signal 0.00
Market Cap $2.0B
TTM Revenue $621.7M
Price / Sales 3.2
ROE -10.1%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C- (2.0) C (2.4) C+ (2.8) A (4.3) C+ (2.6) C+ (2.8)
2026-11-10 D+ (1.6) C+ (2.8) C+ (2.8) A (4.2) C+ (2.6) C+ (2.8)
2026-11-03 C- (2.0) C+ (2.8) C+ (2.8) A- (4.1) C+ (2.7) B- (2.9)
2026-10-27 C- (1.9) C+ (2.8) C+ (2.8) B+ (3.6) C+ (2.6) C+ (2.8)
2026-10-20 C- (2.1) C+ (2.8) C+ (2.8) B+ (3.5) C+ (2.6) C+ (2.8)
Page 1 of 4